Teva to acquire ratiopharm
This article was originally published in The Tan Sheet
Executive Summary
Teva Pharmaceutical Industries' nearly $5 billion (€3.6 billion) pending acquisition of Germany's second-largest generics manufacturer ratiopharm catapults the Israeli company to second place in Germany's generic market. The deal also gives Teva an OTC platform in Germany, which could help the firm gain favor with pharmacists. In Germany, firms can offer pharmacists incentives for choosing specific OTC products, but not for generics. Ratiopharm sells approximately 20 percent non-prescription drugs, including cold and flu remedies, plant-derived medicines and health supplements, according to its Web site. Teva expects the mostly cash deal to be accretive nine months after it closes